IL161325A0 - Substituted benzopyrans as selective estrogen receptor-beta agonists - Google Patents

Substituted benzopyrans as selective estrogen receptor-beta agonists

Info

Publication number
IL161325A0
IL161325A0 IL16132502A IL16132502A IL161325A0 IL 161325 A0 IL161325 A0 IL 161325A0 IL 16132502 A IL16132502 A IL 16132502A IL 16132502 A IL16132502 A IL 16132502A IL 161325 A0 IL161325 A0 IL 161325A0
Authority
IL
Israel
Prior art keywords
estrogen receptor
selective estrogen
beta agonists
agonists
substituted benzopyrans
Prior art date
Application number
IL16132502A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL161325A0 publication Critical patent/IL161325A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL16132502A 2001-11-19 2002-11-07 Substituted benzopyrans as selective estrogen receptor-beta agonists IL161325A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11
PCT/US2002/033622 WO2003044006A1 (en) 2001-11-19 2002-11-07 Substituted benzopyrans as selective estrogen receptor-beta agonists

Publications (1)

Publication Number Publication Date
IL161325A0 true IL161325A0 (en) 2004-09-27

Family

ID=26988373

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16132502A IL161325A0 (en) 2001-11-19 2002-11-07 Substituted benzopyrans as selective estrogen receptor-beta agonists
IL161325A IL161325A (en) 2001-11-19 2004-04-08 Substituted benzopyrans as selective estrogen receptor-beta agonists
IL185867A IL185867A (en) 2001-11-19 2007-09-10 Substituted benzopyrans as selective estrogen receptor-beta agonists

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL161325A IL161325A (en) 2001-11-19 2004-04-08 Substituted benzopyrans as selective estrogen receptor-beta agonists
IL185867A IL185867A (en) 2001-11-19 2007-09-10 Substituted benzopyrans as selective estrogen receptor-beta agonists

Country Status (24)

Country Link
US (1) US7217734B2 (no)
EP (1) EP1448544B1 (no)
JP (1) JP4381810B2 (no)
KR (1) KR100950616B1 (no)
CN (1) CN1312147C (no)
AT (1) ATE362471T1 (no)
AU (1) AU2002359283B2 (no)
CA (1) CA2467013C (no)
CY (1) CY1106726T1 (no)
DE (1) DE60220179T2 (no)
DK (1) DK1448544T3 (no)
EA (1) EA007382B1 (no)
EC (1) ECSP045113A (no)
ES (1) ES2286322T3 (no)
HK (1) HK1068349A1 (no)
HR (1) HRP20040439A2 (no)
HU (1) HU229351B1 (no)
IL (3) IL161325A0 (no)
MX (1) MXPA04004703A (no)
NO (1) NO328563B1 (no)
NZ (1) NZ531850A (no)
PL (1) PL205733B1 (no)
PT (1) PT1448544E (no)
WO (1) WO2003044006A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618102B1 (en) * 2003-04-21 2010-02-10 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
AU2004232798B2 (en) * 2003-04-21 2010-04-22 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
CA2578164A1 (en) 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
ES2361031T3 (es) * 2004-10-18 2011-06-13 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
AU2005307704A1 (en) * 2004-11-18 2006-05-26 Janssen Pharmaceutica N.V. Novel 2H-chromene derivatives as selective estrogen receptor modulators
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
CA2932224A1 (en) 2013-12-05 2015-06-11 Karo Pharma Ab Estrogen receptor beta agonists for use in treating mesothelioma
AU2016324495B2 (en) 2015-09-17 2020-12-03 Institute Of Molecular Genetics As Cr, V.V.I. Carborane compounds and methods of use thereof
US20230114408A1 (en) * 2020-03-11 2023-04-13 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
WO1997009348A2 (en) 1995-09-08 1997-03-13 Karo Bio Ab Orphan receptor
WO1999002512A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
WO2000055137A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
TR200201762T2 (tr) 1999-04-16 2002-10-21 Astrazeneca Ab B östrojen reseptörü ligandları.
CA2396059A1 (en) 1999-12-30 2001-07-12 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU2001256164A1 (en) * 2000-03-01 2001-09-12 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
US6686371B2 (en) 2000-03-27 2004-02-03 Akzo Nobel N.V. Non-steroidal, tetracylic compounds for estrogen-related treatments
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
EP1448544A1 (en) 2004-08-25
CA2467013C (en) 2010-08-10
CA2467013A1 (en) 2003-05-30
NO20042583L (no) 2004-06-18
KR20040063963A (ko) 2004-07-15
CN1589268A (zh) 2005-03-02
ECSP045113A (es) 2004-07-23
MXPA04004703A (es) 2004-08-19
KR100950616B1 (ko) 2010-04-01
IL185867A0 (en) 2008-01-06
AU2002359283B2 (en) 2007-06-21
ATE362471T1 (de) 2007-06-15
AU2002359283B8 (en) 2003-06-10
WO2003044006A1 (en) 2003-05-30
CY1106726T1 (el) 2012-05-23
PL205733B1 (pl) 2010-05-31
US7217734B2 (en) 2007-05-15
DE60220179D1 (de) 2007-06-28
NZ531850A (en) 2007-01-26
JP4381810B2 (ja) 2009-12-09
EA007382B1 (ru) 2006-10-27
US20040249167A1 (en) 2004-12-09
HK1068349A1 (en) 2005-04-29
IL185867A (en) 2009-09-22
CN1312147C (zh) 2007-04-25
IL161325A (en) 2008-07-08
PT1448544E (pt) 2007-08-10
HRP20040439A2 (en) 2005-04-30
PL374510A1 (en) 2005-10-31
NO328563B1 (no) 2010-03-22
HU229351B1 (en) 2013-11-28
EA200400695A1 (ru) 2004-12-30
DK1448544T3 (da) 2007-10-08
HUP0402628A2 (hu) 2005-04-28
ES2286322T3 (es) 2007-12-01
EP1448544B1 (en) 2007-05-16
AU2002359283A1 (en) 2003-06-10
DE60220179T2 (de) 2008-02-07
JP2005513027A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
HK1068349A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CY1110443T1 (el) Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
PT925301E (pt) Derivados altamente lipofilos de camptotecina
RS60503A (en) Substituted alkylamine derivatives and methods of use
NZ511593A (en) Substituted benzopyran analogs for the treatment of inflammation
MY141733A (en) Benzimidazole and pyridylimidazole derivatives as ligands for gabaa receptors
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
AU2001231710A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
HK1080088A1 (zh) 製備c-7取代的5-雄甾烯的方法
WO2003024935A3 (en) Substituted pyrazolyl compounds for the treatment of inflammation
WO2003027075A3 (en) Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
EP1453812A4 (en) CYTOTOXIC AGENTS
AU2002357184A1 (en) SUBSTITUTED 6H-DIBENZO(c,h)CHROMENES AS ESTROGENIC AGENTS
MY117975A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
HUP0402283A3 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine, process for their preparation and pharmaceutical compositions containing them
ES2103237A1 (es) Nuevo compuesto derivado del cromeno
SI1453820T1 (en) Substituted 6h-dibenzo(c,h)chromenes as estrogenic agents